Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access
Alyaa Al-Mughairy/LinkedIn
Mar 9, 2026, 15:36

Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access

Alyaa Al-Mughairy, Pediatric Hematology Oncology Senior Consultant at Ministry of Health Oman,and National Oncology Centre at Royal Hospital, shared Michael Makris‘s post on LinkedIn, adding:

”While standard maintenance doses for Emicizumab in hemophilia A target high plasma concentrations, real-world clinical experience in low economic countries, including our own suggests a low-dose regimens can still effectively maintain a 0.0 Annual bleeding rate for spontaneous bleeds.

This suggests that for many, we may be dosing beyond what is strictly necessary for clinical efficacy based in the standard approved doses.

It’s time to re-consider low doses regimen, ensuring sustainable access driven model of care to all patients without compromising patient safety or posing burden on the healthcare system.”

Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn:

”The approved dose of Hemlibra (emicizumab) is generous, and smaller doses are likely to be effective.

You can read the arguments in my commentary published in the current issue of the Journal of Thrombosis and Haemostasis.”

Title: Is all the approved emicizumab dose essential?

Author: Michael Makris

Read the Full Article on JTH

Alyaa Al-Mughairy: Rethinking Emicizumab Low-Dose Regimens to Ensure Safe and Sustainable Patient Access

Stay updated on all scientific advances with Hemostasis Today.

Alyaa Al-Mughairy bleeding disorders Emicizumab Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today JTH Medicine thrombosis
NewsFeed